Navigation Links
New lymphoma therapies targets diverse and difficult cancer
Date:4/24/2008

NEW YORK (April 24, 2008) -- The fifth leading cause of cancer in the United States, lymphoma is made up of more than 40 rare and highly diverse diseases that target the body's lymphatic system. Lymphomas include both one of the fastest growing cancers -- Burkitt's lymphoma, which can double in size in as little as a day -- and one of the slowest, chronic lymphocytic leukemia (CLL).

While all lymphoma types can be cured or managed as a chronic disease, its complexity and variation do not allow for a one-size-fits-all treatment approach. Instead, it necessitates highly specialized and individualized approaches.

With a dozen new therapies in development -- one of the largest portfolios of lymphoma drugs under development anywhere -- the Herbert Irving Comprehensive Cancer Center of NewYork-Presbyterian Hospital and Columbia University Medical Center is meeting this challenge with highly effective new treatments for the disease, giving hope to the more than one million lymphoma patients worldwide.

In 2006, NewYork-Presbyterian/Columbia recruited Dr. Owen A. O'Connor, one of the world's top lymphoma researchers, to lead its Lymphoid Development and Malignancy Program, and direct more than 25 full-time scientists and physician scientists.

"By increasing the number and quality of treatment options for lymphoma patients, we are improving their chances for survival. This is especially critical for patients who haven't responded to standard therapies," says Dr. O'Connor, who is also chief of the Lymphoma Service at NewYork-Presbyterian/Columbia and associate professor of medicine at Columbia University College of Physicians and Surgeons.

One of the most promising new therapies developed at NewYork-Presbyterian/Columbia is PDX (pralatrexate) for T-cell lymphoma -- among the most fatal forms of the disease. The drug is uniquely designed to camouflage itself as a folic acid, which allows it to be absorbed by the tumor, wher
'/>"/>

Contact: Jennifer Homa
jeh9057@nyp.org
212-305-5587
New York- Presbyterian Hospital/Columbia University Medical Center
Source:Eurekalert

Page: 1 2

Related medicine news :

1. The Leukemia & Lymphoma Society Hosts Workshop On Weighing Treatment Options For Chronic Myelogenous Leukemia
2. The Leukemia & Lymphoma Society Provides Patients with the Latest Information on Myeloma
3. Cell Therapeutics, Inc. (CTI) Plans to Submit Supplemental Biologics License Application (sBLA) for ZEVALIN(R) Consolidation of First Remission in Advanced Stage Follicular Lymphoma in 2008
4. January 1 Looms Large for Lymphoma Patients
5. Micromet and MedImmune to Present New Clinical Data for Anti-CD19 BiTE(R) Antibody at American Society of Hematology Annual Meeting Showing Objective Clinical Responses in Relapsed Non-Hodgkins Lymphoma Patients
6. Possible Cure for Rare Lymphoma Reported
7. Pharmion and Methylgene Report Favorable Results for Phase 2 MGCD0103 Single- Agent Studies in Relapsed or Refractory Lymphomas at the 49th American Society of Hematology (ASH) Meeting
8. Gentler chemotherapy before stem cell transplant causes long-term remission of follicular lymphoma
9. Genmab Initiates Ofatumumab Phase II Study in Diffuse Large B-Cell Lymphoma
10. Lymphoma drug used to treat skin disorders
11. Firefly genes allow testing of new therapy against lymphoma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2014)... 31, 2014 USHIO America’s Solid ... and general lighting marketplaces, today announced the launch ... will allow users to transform existing, inefficient lamp-based ... minutes. , USHIO America’s Uphoria LED downlight retrofit ... cans, allowing the user to upgrade old incandescent ...
(Date:7/31/2014)... Palm Coast Florida (PRWEB) July 31, 2014 ... the agenda for the upcoming inaugural Clinical Issues ... to be held October 13-17, 2014 at the Wailea ... " This incredible agenda has been developed for ... many of the critical CME topics," says Barbara Lyons, ...
(Date:7/31/2014)... 2014 The study, The Truth ... Medicare episode of care payments for four clinical areas—congestive ... joint replacements (hips and knees). Using the definition ... for Care Improvement program, the study examines these clinical ... in the country. , “Our study reaffirms that, in ...
(Date:7/30/2014)... Push to Walk and Macy’s invite customers ... A Cause” charity shopping event on August 23, 2014. ... shopping event created to support local charities’ fundraising efforts, ... charities across the country since 2006. Customers can participate ... Push to Walk now. , “Macy’s is ...
(Date:7/30/2014)... 31, 2014 CareSource, a nonprofit, Ohio-based ... President and CEO, Wright-Patt Credit Union, to the CareSource ... foremost financial CEO with an extensive background in leading ... and later chief operating officer at Wright-Patt Credit Union ... the Beavercreek-based Wright-Patt Credit Union that has realized more ...
Breaking Medicine News(10 mins):Health News:USHIO America Introduces Uphoria™ LED Downlight Retrofit Kits 2Health News:Clinical Issues in Primary Care Continuing Medical Education (CME) Conference - October 13-17, 2014 in Maui, Hawaii - Agenda Released 2Health News:Clinical Issues in Primary Care Continuing Medical Education (CME) Conference - October 13-17, 2014 in Maui, Hawaii - Agenda Released 3Health News:Recent Research Finds a New Driver of Cost Variation in Episode Payments 2Health News:Recent Research Finds a New Driver of Cost Variation in Episode Payments 3Health News:Push to Walk Participates in Macy’s Ninth Annual “Shop For A Cause” 2Health News:Push to Walk Participates in Macy’s Ninth Annual “Shop For A Cause” 3
... , , , , ... Pioneering Innovation Award today at the Centers for Disease Control and ... These organizations are being recognized for their work in advancing policies ... With rising rates of obesity in adults, particularly those ...
... ... consumers to be aware of non-approved cosmetic injections , ... (PRWEB) July 29, 2009 -- The Physicians Coalition ... products, touting everything from cellulite treatment to weight loss are not FDA approved, and ...
... CLEARWATER, Fla., July 29 BayCare Health System today announced ... To Work For by Florida Trend magazine . ... medium and large companies, were compiled from surveys of participating companies, employees ... the August issue of Florida Trend and on FloridaTrend.com. , ...
... , NEW ORLEANS, July 29 ... showing its pioneering spirit again by leading the way to making healthy ... , , Consumers in Tokyo will be the ... with the first store planned to open in 2010. Japan makes sense ...
... EMERYVILLE, Calif., July 29 Bionovo, Inc. (Nasdaq: ... the unmet needs in women,s health and oncology, today announced that ... Senior Vice President and CFO, will be presenting at the BMO ... EDT on Wednesday, August 5, 2009. The event will be held ...
... day cut risk in half in study of Finnish men ... associated with moderate- to high-intensity exercise appears to reduce the ... Finnish study included 2,560 men, aged 42 to 61, whose ... the men had a history of cancer, according to the ...
Cached Medicine News:Health News:CDC Recognizes Innovative Obesity Prevention and Control Initiatives With Weight of the Nation Awards 2Health News:CDC Recognizes Innovative Obesity Prevention and Control Initiatives With Weight of the Nation Awards 3Health News:CDC Recognizes Innovative Obesity Prevention and Control Initiatives With Weight of the Nation Awards 4Health News:Carboxytherapy and Mesotherapy Unproven, Warns The Physicians Coalition for Injectable Safety 2Health News:Carboxytherapy and Mesotherapy Unproven, Warns The Physicians Coalition for Injectable Safety 3Health News:BayCare Named to Top 100 Best Companies To Work For in Florida by Florida Trend Magazine 2Health News:BayCare Named to Top 100 Best Companies To Work For in Florida by Florida Trend Magazine 3Health News:Smoothie King Expansion Signals International Trend Toward Healthy Living 2Health News:Smoothie King Expansion Signals International Trend Toward Healthy Living 3Health News:Bionovo to Present at the BMO Capital Markets Ninth Annual Focus on Healthcare Conference 2
(Date:7/30/2014)... July 30, 2014  InnoPharma, Inc. today announced the ... generic equivalent of Zyprexa® injection), in Canada.  Olanzapine is ... behaviors in patients with schizophrenia or bipolar I mania. ... drug, InnoPharma has entered into an agreement with Sandoz ... will make, use, sell, market and distribute Olanzapine Injection ...
(Date:7/30/2014)... and PARIS , July 30, ... ) and Sanofi (EURONEXT: SAN and NYSE: ... ODYSSEY trials of alirocumab in people with hypercholesterolemia met ... from baseline in low-density lipoprotein cholesterol (LDL-C) at 24 ... an investigational monoclonal antibody targeting PCSK9 (proprotein convertase subtilisin/kexin ...
(Date:7/30/2014)... NEW YORK , July 30, 2014 ... products for oncology supportive care, announced that its novel ... featured in an article on OncLive.com titled, "Study Finds ... Neck Cancers."  Dr. Steve Sonis , a leading ... demand seen in the oncology community for evidence-based strategies ...
Breaking Medicine Technology:InnoPharma Announces Launch of Olanzapine for Injection, 10mg/vial in Canada 2Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 2Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 3Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 4Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 5Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 6Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 7Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 8Access Pharmaceuticals Featured On OncLive.com 2Access Pharmaceuticals Featured On OncLive.com 3
... /PRNewswire-Asia-FirstCall/ -- Golden Meditech Holdings ("Golden Meditech," 0801.HK, ... Bon International") today announced that the companies have ... strategic cooperation in Taipei.  Golden Meditech Holdings Chairman, ... International, Mr. Chu Powei, respectively represented and co-chaired ...
... BRUNSWICK, N.J., and LEIDEN, Netherlands, Feb. 17, 2011 ... (NYSE Euronext, Nasdaq: CRXL ; Swiss Exchange: CRX) today ... to acquire Crucell N.V. (Crucell) has been satisfied.  The initial offering ... a.m. New York time) on 16 February 2011.   ...
Cached Medicine Technology:Golden Meditech to Form Strategic Alliance with Long Bon International 2Golden Meditech to Form Strategic Alliance with Long Bon International 3Minimum Acceptance Condition Satisfied 2Minimum Acceptance Condition Satisfied 3Minimum Acceptance Condition Satisfied 4Minimum Acceptance Condition Satisfied 5Minimum Acceptance Condition Satisfied 6
A new flexible endoscope with an ultra dense optic fiber system. Its two working and irrigation channels and steering mechanism makes it ideal for a multipurpose use in neurosurgical endoscopy i.e. V...
... Performance Instrument System. It is the only ... electric power with the unparalleled high performance ... The advanced design of this instrument system ... cooling system, advanced control circuitry, and the ...
The XK-PRO 100 High Speed Drill System is a compact, lightweight design that offers new technological and performance standards for a combination of surgical procedures....
... The Legend Platinum is a compact ... 77,000 rpm at 120 psi/8 bar, ... of comparable size with noticeable noise ... design combines with an enhanced ergonomic ...
Medicine Products: